FDA MedWatch Alert Warns Of Possible Suicide Risk With Singulair
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency needs nine months to review post-marketing data on Merck asthma drug due to the complexity of the information.
You may also be interested in...
Singulair And Suicidality: FDA Finds No Immediate Link, But Review Continues
FDA is continuing to review a possible relationship between the use of Merck's Singulair (montelukast) and an increased risk of suicidality despite finding no association so far between leukotriene pathway drugs and mood behaviors
Singulair And Suicidality: FDA Finds No Immediate Link, But Review Continues
FDA is continuing to review a possible relationship between the use of Merck's Singulair (montelukast) and an increased risk of suicidality despite finding no association so far between leukotriene pathway drugs and mood behaviors
FDA Issues Suicidality Alert On Antiepileptics
A class-wide relabeling is expected, but Pfizer says that Neurontin and Lyrica show no signs of increased events.